Published in MD Week, September 3rd, 2004
According to recent research published in the journal Transplantation, "interferon treatment of hepatitis C virus (HCV) infection in transplant recipients carries a high risk of rejection. We treated these patients with ultralow-dose interferon-alpha (1x106 units subcutaneously three times/week) plus ribavirin (600 mg/day) for 48 weeks. Treatment efficacy was evaluated by the changes of serum liver enzymes and viral load."
"A total of 11 patients were recruited for the study; biochemical response was obtained in all patients but 1. Three patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of MD Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.